{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:55:22Z","timestamp":1790765722933,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":2253,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1124\/dmd.118.083337","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T17:15:32Z","timestamp":1535735732000},"page":"1546-1555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro"],"prefix":"10.1016","volume":"46","author":[{"given":"Michael","family":"Gerisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Heinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Platzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.083337_bib1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1124\/dmd.118.083337_bib2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1023\/A:1010927026837","article-title":"The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs","volume":"18","author":"Basit","year":"2001","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.118.083337_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1124\/dmd.118.083337_bib4","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.118.083337_bib5","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1124\/dmd.118.083337_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00280-017-3480-9","article-title":"Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects","volume":"81","author":"Gerisch","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.118.083337_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s13318-018-0483-9","article-title":"Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo","author":"Heinig","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.118.083337_bib8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.118.083337_bib9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1042\/bj1291071","article-title":"Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions","volume":"129","author":"Hirom","year":"1972","journal-title":"Biochem J"},{"key":"10.1124\/dmd.118.083337_bib10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.083337_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0006-2952(97)00204-9","article-title":"Drug metabolism in hepatocyte sandwich cultures of rats and humans","volume":"54","author":"Kern","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.118.083337_bib12","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1124\/dmd.118.083337_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/dmd.118.083337_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1124\/dmd.118.083337_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/cmdc.201000485","article-title":"Revealing atropisomer axial chirality in drug discovery","volume":"6","author":"LaPlante","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1124\/dmd.118.083337_bib16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.118.083337_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/03602539808996322","article-title":"Sex-dependent metabolism of xenobiotics","volume":"30","author":"Mugford","year":"1998","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.118.083337_bib18","first-page":"319","article-title":"Variables in human liver microsome preparation: impact on the kinetics of l-\u03b1-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation","volume":"29","author":"Nelson","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.083337_bib19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3109\/00498258009108376","article-title":"Enterohepatic recycling of phenolphthalein, morphine, lysergic acid diethylamide (LSD) and diphenylacetic acid in the rat. Hydrolysis of glucuronic acid conjugates in the gut lumen","volume":"10","author":"Parker","year":"1980","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.118.083337_bib20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/dmd.118.083337_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.ackd.2014.08.003","article-title":"Aldosterone blockade in CKD: emphasis on pharmacology","volume":"22","author":"Schwenk","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1124\/dmd.118.083337_bib22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1208\/s12248-009-9124-1","article-title":"Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships","volume":"11","author":"Yang","year":"2009","journal-title":"AAPS J"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624056381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624056381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.083337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:03:51Z","timestamp":1740765831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624056381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0090955624056381"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.083337","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.083337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The Author(s)","name":"copyright","label":"Copyright"}]}}